1.	An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma Phase: Phase IV Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: U2963n, NCT00097565
2.	Non-Myeloablative Allogeneic HSCT From HLA Matched Related Donors for the Treatment of Low Grade B Cell Malignancies Phase: Phase III, Phase II Type: Treatment Status: Active Age: 19 to 70 Sponsor: Other Protocol IDs: F080429003, UAB-0775, NCT00714259
3.	HuMax-CD20 in FL Patients Refractory to Rituximab Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Hx-CD20-405, NCT00394836
4.	A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: U4391g, NCT00719472
5.	Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: MSKCC-95024, NCI-V95-0685, NCT00002663
6.	Phase I/II CPG 7909 + Local XRT in Recurrent Low-Grade Lymphomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: LYMNHL0014, 80057, LYMNHL0014, NCT00185965, NIH, NCT00185965
7.	Phase I/II Study of Fenretinide and Rituximab in Patients With B-Cell Non-Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: WU-6071, 6071, FHCRC-6071, NCI-6957, 6957, UWCC-UW-6071, UWCC-06-0644-H/A, NCT00288067
8.	A Study of SB-743921 in Non-Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CY 2121, NCT00343564
9.	Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
10.	A Phase I/II Trial of VR-CHOP in Lymphoma Patients Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IRB# 29960007, NCT00634179
11.	Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 0 to 55 Sponsor: Other Protocol IDs: 8717, NCT00673114
12.	Study of AMD3100 and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: MOZ00207, NCT00694590
13.	Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-0403, NCT00724984
14.	SAHA + CHOP in Untreated T-Cell Non-Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0484, NCT00787527
15.	Phase I/II Study of T-Cell-Reduced Unrelated Donor Peripheral Blood Stem Cell Transplantation After Reduced-Intensity Conditioning Comprising Pentostatin and Low-Dose Total-Body Irradiation in Patients With Hematological Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 19 to 75 Sponsor: NCI Protocol IDs: UNMC-16407, 164-07, NCT00816413
16.	Phase II Study of Rituximab and Fludarabine in Patients With Intermediate- or High-Risk Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-97-C-0178, NCT00019370
17.	Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Low Grade Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BC-LY-6, NCT00003499
18.	Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancy Phase: Phase II Type: Treatment Status: Active Age: 65 and under Sponsor: NCI Protocol IDs: CPMC-IRB-AAAA5571, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
19.	Phase II Pilot Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-CTLA4) in Patients With Follicular or Mantle Cell Lymphoma, Colon Cancer, Prostate Cancer Refractory to Vaccine Therapy (Prostate cancer and mantle cell lymphoma closed to accrual as of 3/10/2005; colon cancer closed to accrual as of 9/28/05),Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-02-C-0284, NCI-5744, NCT00047164, 5744
20.	Phase II Study of Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan as First-Line Treatment in Patients With Indolent Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: BIDMC-2004P-000044, NCT00110149
21.	Phase II Study of Immunotherapy Comprising Rituximab, Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine (FavId™), and Sargramostim (GM-CSF) in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: FAV-ID-70, FAV-ID-LYM-31, NCT00258336
22.	Phase II Study of Rituximab, High-Dose Cyclophosphamide, and Pegfilgrastim in Patients With B-Cell Leukemia or Low-Grade or Mantle Cell Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: NCI Protocol IDs: JHOC-J0260, J0260, JHOC-03022409, NCT00278161
23.	Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF and Rituximab Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 1048-2001, NCT00208975
24.	Phase II Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: LYMNHL0020, 4328-07, 95140, LYMNHL0020, NCT00185731, NCT00185731
25.	Clinical Trial of PXD101 in Patients With T-Cell Lymphomas Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PXD101-CLN-6, NCT00274651